Gastrointestinal

This course provides a summary of the following abstracts:

  • Nonoperative management versus surgery in patients with complete endoscopic response to neoadjuvant therapy for rectal cancer
  • Complete clinical response after short-course radiation and sequential multi-agent chemotherapy for non-operative treatment of rectal adenocarcinoma
  • A Genotype Signature for Predicting Pathologic Complete Response in Locally Advanced Rectal Cancer
  • Serial Circulating Tumor DNA for Evaluating Early Response During Chemoradiotherapy for Locally Advanced Esophageal Squamous Cell Carcinoma: Preliminary Analysis of A Prospective Biomarker Study
  • Phase I Study of Stereotactic Body Radiotherapy followed by Ipilimumab with Nivolumab vs. Nivolumab alone in Unresectable Hepatocellular Carcinoma
  • Relationship of Dose to Vascular Target Volumes and Local Failure in Pancreatic Cancer Patients Undergoing Neoadjuvant Chemoradiation
  • Stereotactic Body Radiotherapy vs Transarterial Chemoembolisation in locally advanced hepatocellular carcinoma (HERACLES: HEpatocellular carcinoma stereotactic RAdiotherapy CLinical Efficacy Study)

 

Target Audience

The course is designed to meet the interests of practicing radiation oncologists, radiation oncology residents, medical and clinical physicists, surgeons, physicists, nurses, diagnostic radiologists, pathologists, radiation therapists, radiation dosimetrists, and all other health professionals involved in the field of radiation oncology.

Learning Objectives

Upon completion of this activity, learners should be able to do the following:

  • Recognize the role of non-operative management of rectal cancer and which candidates may be best suited for this approach
  • Identify potential ways to optimize pancreatic SBRT
  • Describe the role of SBRT for hepatocellular carcinoma in combination with immune therapy and how SBRT compares to TACE
Course summary
Available credit: 
  • 1.00 AMA PRA Category 1 Credit™
    The American Society for Radiation Oncology (ASTRO) is accredited by the Accreditation Council for Continuing Medical Education for physicians. ASTRO designates this for a maximum of 1.00 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
  • 1.00 Certificate of Attendance
    This activity was designated for 1.00 AMA PRA Category 1 Credit™.
Course opens: 
01/01/2021
Course expires: 
12/31/2023
Cost:
$0.00
Parent activity set: 
Rating: 
0

Gastrointestinal
Daniel Chang, MD is employed  by Stanford University and receives compensation/remuneration/funding from Varian Medical Systems and has stock in ViewRay.

The American Society for Radiation Oncology (ASTRO) is accredited by the Accreditation Council of Continuing Medical Education to provide continuing education to physicians.

Available Credit

  • 1.00 AMA PRA Category 1 Credit™
    The American Society for Radiation Oncology (ASTRO) is accredited by the Accreditation Council for Continuing Medical Education for physicians. ASTRO designates this for a maximum of 1.00 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
  • 1.00 Certificate of Attendance
    This activity was designated for 1.00 AMA PRA Category 1 Credit™.

Price

Cost:
$0.00
Please login or register to take this course.